Market Overview The US alpha thalassemia market is experiencing access emphasis where insurance coverage, patient assistance programs, and affordability initiatives enable treatment access and adherence. The US alpha thalassemia market is projected to exceed USD 0.85 billion through 2030, with access emphasis driven by medication costs, insurance variations, and equity concerns. Access...